VitriVax
Boulder, Colorado, United States · Biotechnology, Therapeutics · 135 employees
VitriVax is a formulation technology company developing innovative solutions to maximize the global accessibility and utility of human and animal vaccines. Our ALTA® platform makes vaccines thermostable up to 70°C and single-shot, combining prime and boost doses into a single injection.
Funding history
- Funding Round — $29.4M — Nov 2025
- Funding Round — $9.9M — Oct 2025
Recent signals
- Nov 17, 2025: Raised $29.4M
- Oct 14, 2025: Raised $9.9M
See plans & pricing → Track VitriVax’s funding, hiring, and signals — with verified contacts — on Fundz.